 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
111 News |  |
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3668;
P2a
Table: 2237P Conclusions Independently of RAS mutation, existing adaptive immune response within metastases is associated with treatment benefit. ctDNA decrease is associated with tumor response.
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2219;
P2a
Conclusions Despite good tolerability, AVETUXIRI trial did not reach its efficacy endpoint. IS could be a predictive biomarker for selecting patients with potential treatment benefits.
- || Avent (etanercept biosimilar) / Avesthagen
"Les morts sont pati" Oui mon ami. Faudrait pas oublier de prendre votre sirop avent de dormir. (Twitter) - Feb 20, 2023
- | Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. (Pubmed Central) - Jan 7, 2023
P2
In summary, we report the final overall survival of the AVETUX trial and propose T cell clonality and diversity as a potential marker to predict response to chemo-immunotherapy combinations in MSS mCRC by performing a central radiological review. ClinicalTrials.gov, identifier (NCT03174405).
- || Avent (etanercept biosimilar) / Avesthagen
@23andMe Hi, My Birthday is January 6, 2023. Do you have daily, avent company birthday giveaway/assistance gifts to share leading up and also now? (Twitter) - Jan 1, 2023
- || Avent (etanercept biosimilar) / Avesthagen
Encore un article spécial #Noel #Christmas @bmj_latest Un calendrier de l’avent de l’activité physique 🏃🏾♀️🏃🏾♂️🏃🏾https://t.co/EGh11lTCN1 (Twitter) - Dec 21, 2022
- ||| Avent (etanercept biosimilar) / Avesthagen
Pouvez vous me parler des gens crado qui se l'avent pas les mains et choppes des infections ? (Twitter) - Dec 7, 2022
- ||| Avent (etanercept biosimilar) / Avesthagen
Le calendrier de l'Avent des publications des membres du GAVO2. J-18. @DrGonzalezJesus et ses collègues montrent que les impressions 3D comme pièce de VNI c'est bof.. https://t.co/HAbZh8UD58 (Twitter) - Dec 7, 2022
- || Avent (etanercept biosimilar) / Avesthagen
@AstraZenecaFR et @Pfizer_France ont sorti un calendrier de l'avent... (Twitter) - Dec 5, 2022
- Bavencio (avelumab) / EMD Serono, Pfizer
Selection of PD-L1 escape variants in microsatellite stable metastatic colorectal cancer on avelumab treatment (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_3208;
P2
The patient received 4 cycles of FOLFIRI/cetuximab, followed by 4 cycles FOLFIRI/cetuximab + avelumab, followed by avelumab maintenance treatment for 10 weeks until end of treatment (EOT) due to progression in week 19...Together with the emergence of truncated PD-L1 variants, regulation of PD-L1 availabilty but not epitope disruption appears to be the key mechanistic principle towards PD-L1 escape. Future trials confirming this principle in other entities are warranted especially in patient subpopulations with rs396991.
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC). (Available On Demand; 389) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1396;
P2a
Encouraging survival data observed in RAS-mut cohort allow the opening of a new cohort (PFS as primary endpoint). IS and adaptive immune response signature evaluated on metastases biopsies were associated with treatment efficacy and survival.
- ||| Avent (etanercept biosimilar) / Avesthagen
@DrTedros of @WHO is completely compromised by CCP China. Sycophant @DrTedros is equally responsible just like CCP for unleashing this SARSCOV2 Coronavirus pandemic all over the world due to his phony statements from the very avent of this virus. @nytimes should scrutinize (Twitter) - Nov 27, 2021
- | Avent (etanercept biosimilar) / Avesthagen
$PHG Philips Avent Evolves Portfolio with Suite of Product Innovations and Enhancements https://t.co/8t6laUdnPo (Twitter) - Sep 1, 2021
- | Avent (etanercept biosimilar) / Avesthagen
$PHG Philips Avent Launches New Electric Breast Pump Inspired by Baby's Natural Feeding Motion https://t.co/QO1G4V8469 (Twitter) - Mar 9, 2021
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] O07: INTERIM ANALYSIS OF THE AVETUXIRI TRIAL: AVELUMAB COMBINED WITH CETUXIMAB AND IRINOTECAN FOR TREATMENT OF REFRACTORY MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER (mCRC) – A PROOF OF CONCEPT, OPEN LABEL, NON-RANDOMIZED PHASE IIA STUDY. (mC () - Feb 23, 2021 - Abstract #BWG2021BWG_54;
P2a
Methods AVETUXIRI (NCT03608046) is a multicenter academic study recruiting MSS, BRAFV600E wt, mCRC patients (pts) refractory to standard treatment (fluoropyrimidine, oxaliplatin, irinotecan and anti-EGFR treatment if RAS wt tumor) in 2 cohorts (cohort A: RAS wt – cohort B: RAS mut)...Nevertheless, encouraging data of DCR, PFS and OS observed in RAS mut cohort allow the opening of a new cohort for RAS-mut mCRC (cohort C) with PFS as primary endpoint. A high-Immunoscore was associated with treatment benefit.
- || Avent (etanercept biosimilar) / Avesthagen
Excited to see that this day has arrived for @InaParkMD and grateful to be privileged to receive a portion of proceeds. The goal of the Kirk Avent Support Fund is to further the medical education mission of the division and fellowship program! #IDtwitter #IDMedEd @DrJeanneM (Twitter) - Feb 2, 2021
- || Avent (etanercept biosimilar) / Avesthagen
On a tellement besoin de #culture pour se rassembler en cette période merci @CultureUGA pour ce calendrier de l'Avent qui donne la parole aux étudiants @VanessaDelfau @MChBordeaux #UGAonEstEnsemble #vieetudiante #icampus https://t.co/43oZr14tzV (Twitter) - Dec 19, 2020
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_67;
P2a
No PR was observed in RAS-mut cohort. Nevertheless, encouraging data of DCR, PFS and OS observed in RAS mut cohort allow the opening of a new cohort for RAS-mut mCRC (cohort C) with PFS as primary endpoint.
- | Avent (etanercept biosimilar) / Avesthagen
Observational data, Journal: Adaptive capacity of 2- to 5-month-old infants to the flow, shape, and flexibility of different teats during bottle feeding: a cross-sectional study. (Pubmed Central) - Nov 19, 2020
Nevertheless, encouraging data of DCR, PFS and OS observed in RAS mut cohort allow the opening of a new cohort for RAS-mut mCRC (cohort C) with PFS as primary endpoint. Healthy infants aged 2-5 months can adapt to the flow, shape, and flexibility of different teats, showing a wide range of biomechanical and motor adaptations.
- || Avent (etanercept biosimilar) / Avesthagen
Bibou is closed, and Pierre and Charlotte Calmels plan to reopen it as a French grocery -- Moi, je suis un peu desole mais aussi cette nouvelle est excite. En avent! https://t.co/oIQjgygeUy via @phillyinquirer (Twitter) - Aug 21, 2020
- || Avent (etanercept biosimilar) / Avesthagen
Clinical, Journal: Tracker-Based Personal Advice to Support the Baby's Healthy Development in a Novel Parenting App: Data-Driven Innovation. (Pubmed Central) - Jul 29, 2020
The insights development process we followed showed how the quality of insights can be guaranteed by ensuring that insights are relevant, appropriate, and evidence based. In this way, insights are an example of meaningful DDI.
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). (Level 1, West Hall - Poster Board E4) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_847;
P2
The noted ORR/ETS of 79.5% warrants further evaluation in a randomized trial. Clinical trial information: NCT03174405.
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). (Level 1, West Hall - Poster Board E4) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_217;
P2
The noted ORR/ETS of 79.5% warrants further evaluation in a randomized trial. Clinical trial information: NCT03174405.
- |||| Clinical: Abstracts of interest for the #COLORECTAL community, related to #clinicaltrials, to be presented at #SITC2019 (Nov. 6-10): AVETUX, PolyPEPI1018, alloSHRINK, SHRINK, COM701 and more. #CRCSM (Twitter) - Nov 5, 2019
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Avetux (rituximab biosimilar) / Avesthagen
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) – Final Results of the phase II AVETUX trial (AIO-KRK-0216) (Prince George's Exhibition Hall C) - Oct 2, 2019 - Abstract #SITC2019SITC_301;
The AVETUX regimen was feasible producing a high rate of responses in MSS pts mainly occurring within the first 8 weeks. The noted ORR/ETS of 79.5% warrants further evaluation in a randomized trial.